医師の一分

アクセスカウンタ

zoom RSS 出荷停止の禁煙補助薬チャンピックスが供給再開へ

<<   作成日時 : 2011/01/06 20:08   >>

なるほど(納得、参考になった、ヘー) ブログ気持玉 1 / トラックバック 0 / コメント 1

 日本政府が10月1日にタバコ税を引き上げたことで、ヘビースモーカーの国に公衆衛生改革が起こるかもしれない。
画像 増税は禁煙薬を販売する世界企業ファイザーの金鉱脈となるはずだったが、その機会を逸してしまった。ファイザーは医師に押し寄せた数万人の禁煙希望者にたいして十分なチャンピックスChampixの生産ができず、販売を中断する事態となったため、数百万ドルを失ったことになる。
 日本では喫煙者はずっと守られてきた。安いタバコと喫煙の自由がその習慣を維持してきた。WHOによれば、日本では年間約13万人がタバコ関連で死亡している。
 しかし徐々に喫煙規制は進行してきた。喫煙率は1年前より2.3%低下し2010年で36.6%となったが、米国の24%に比べてずっと高い。
 10月1日に20本パックが300円から400円に引き上げられ、70円増税された。値上げ前に喫煙者は大量に買い入れたため9月の売上げは88%増加したが、10月には70%低下した。調査によれば13.9%が禁煙し、15.5%が禁煙を計画している。
(書きかけ)
------------------------------
これから禁煙治療の開始をご希望の方へ
http://sugu-kinen.jp/

大変長らくお待たせし申し訳ありませんでした。
弊社の禁煙のための飲み薬の需要が急激に増加し、弊社製造販売の飲み薬による禁煙治療を開始することがここ数ヶ月難しい状況でしたが、2011年1月初旬より、飲み薬による禁煙治療を開始できる体制が整いましたので、ご案内させて頂きます。
弊社では引き続き、患者様の健康のために禁煙治療をサポートしてまいります。

ファイザー株式会社 お問い合わせ先:0120-933-917

----------------------------------------------------
In Japan, Pfizer Is Short of Drug to Help Smokers
http://www.nytimes.com/2011/01/04/business/global/04smoke.html

By HIROKO TABUCHI
Published: January 3, 2011

画像TOKYO ― When the Japanese government raised the tax on cigarettes on Oct. 1, it could have started a public health revolution in this land of heavy smokers.

The tax increase should also have been a bonanza for Pfizer, the world’s biggest pharmaceutical company, which makes the leading drug to help smokers break the habit.

Instead, it became a missed opportunity.

Despite ample notice of the change, Pfizer failed to produce enough of the drug, Chantix, which is sold as Champix in Japan. When tens of thousands of would-be quitters rushed to their doctors for prescriptions, Pfizer was overwhelmed.

Less than two weeks after the tax increase went into effect, the company was forced to suspend sales of the drug to new patients until it could ramp up production.

Now, with the drug still difficult to get, Japanese health professionals and many of the nation’s smokers are grumbling.

And Pfizer has given up millions of dollars in potential Chantix sales, at least temporarily, at a time when overseas markets are growing in importance. In the United States, prescriptions for the drug plunged after the Food and Drug Administration warned doctors about psychiatric side effects.

“After all that advertising, it turns out they don’t have enough,” said Hiroya Kumamaru, director of the KI Akihabara Clinic in Tokyo, who is turning away patients. His clinic has enough of the drug for only the 80 patients who began their treatment before the supply squeeze. “They should have predicted something like this,” he said.

A Pfizer spokesman in Tokyo, Kinji Iwase, said the company misjudged interest in the drug among Japanese smokers. “An extraordinary number of people decided to quit, and our reading of the situation was off,” Mr. Iwase said. “We expected more demand, but not to this extent.”

Japan has long been a smokers’ stronghold. Cheap cigarettes sold by a government-controlled tobacco company and lax antismoking laws ― smokers have almost total freedom to light up at bars, restaurants and even schools and government offices ― have long encouraged the habit. About 130,000 people a year die of tobacco-related illnesses in Japan, according to the World Health Organization.

But a growing health consciousness, tighter regulations on tobacco advertising and increasingly strict smoking bans on public transport have contributed to a gradual decline in smoking. The smoking rate for men was 36.6 percent in 2010, 2.3 percentage points lower than a year earlier ― though far above the 24 percent smoking rate among men in the United States.

The tax increase, prompted by health concerns as well as a need to raise revenue for Japan’s government, was expected to spur an even more sharp and sustained flight from cigarettes. On Oct. 1, the price of a pack of 20 cigarettes jumped from 300 yen, or about $3.60, to over 400 yen, including 70 yen in taxes.

Ahead of the increase, smokers rushed to stock up; tobacco sales surged 88 percent in September from a year earlier, but slumped 70 percent in October, according to the Tobacco Institute of Japan.

Surveys suggest that many smokers here are looking to quit. In one November poll of 1,110 smokers by Rakuten Research, 13.9 percent of respondents said they had stopped smoking, while 15.5 percent said they planned to stop.

While sales of nicotine patches and smoking alternatives have risen, Chantix seems to be the preference for smokers trying to stop.

Introduced in the United States in 2006, Chantix, which works by blocking receptors in the brain and suppressing the positive feelings induced by cigarettes, was initially seen as a global blockbuster. But reports of possible side effects, including aggression and thoughts of suicide, prompted the F.D.A. in 2009 to require the drug to carry the agency’s strongest warning on its packaging. That set off a sharp drop in sales in the United States.

Since then, Pfizer has tried to emphasize the benefits of quitting smoking over the risks posed by Chantix, and has stressed that further studies are needed to determine whether the problems are caused by the drug itself or are symptoms of nicotine withdrawal.

To make up for lost revenue at home, Pfizer has also looked increasingly to foreign markets. In the first nine months of 2010, while revenue from Chantix in America fell another 16.8 percent to $252 million, sales in the rest of the world grew 22.17 percent to $270 million.

Clearing Japan’s drug-approval process in 2008, Pfizer successfully wooed Japanese doctors to prescribe the drug. Japan’s national health insurance covered 70 percent of the 60,000-yen cost for a recommended 12-week prescription.

To stoke public interest, Pfizer started a major ad campaign, starring the slick Hiroshi Tachi, Japan’s answer to the chain-smoking Don Draper of America’s “Mad Men.” Mr. Tachi declared that Chantix had helped him quit smoking, and posed in posters with a party horn between his fingers instead of his trademark cigarette. Soon, Japanese blogs raved about the new “almighty” drug that would help Japan kick its cigarette habit. (There has been little coverage here of Chantix’s potential side effects.)

By August, Pfizer was selling the drug to about 70,000 patients a month in Japan. But that did not prepare the company for the jump in demand related to the tax increase. In September, prescriptions more than doubled to 170,000, and they rose even more in October.

On Oct. 12, Pfizer announced that it was stopping shipments of its “starter packs,” and instructed clinics to stop accepting new patients.

Reiko Ono, 33, who has smoked for over a decade, was one of the last to secure supplies of Champix at a Tokyo clinic. She has completed eight of the 12 weeks of recommended treatment, and has, until now, resisted the urge to light up.

“It hasn’t been as difficult as I thought,” Ms. Ono said.

But many of Ms. Ono’s colleagues who sought the drug were told to wait, she said. “I’m lucky I moved quickly,” she said.

Particularly irritating to many smokers is that Pfizer had almost a year to prepare for a surge in demand; the tax increase was approved in December 2009.

Pfizer is now reassuring would-be customers that they, too, will soon have access to Chantix. In January, the drug maker says, it will have at least 450,000 starter packs available.

Health professionals say that further reductions in smoking-related deaths will hinge on whether the government levies further taxes on cigarettes, which remain cheaper than in the United States and Europe, and bucks the influence of Japan Tobacco, still half-owned by the Finance Ministry.

The Democratic Party of Japan, which took power after the 2009 elections, has been more proactive in setting a nonsmoking agenda, and some lawmakers are pressing to do much more.

“This is just the first step. An ideal scenario is to raise tobacco prices to as much as 1,000 yen,” a Democratic lawmaker, Yoko Komiyama, said. “Whatever it takes to get more people to quit.”

テーマ

関連テーマ 一覧


月別リンク

ブログ気持玉

クリックして気持ちを伝えよう!
ログインしてクリックすれば、自分のブログへのリンクが付きます。
→ログインへ
気持玉数 : 1
なるほど(納得、参考になった、ヘー)

トラックバック(0件)

タイトル (本文) ブログ名/日時

トラックバック用URL help


自分のブログにトラックバック記事作成(会員用) help

タイトル
本 文

コメント(1件)

内 容 ニックネーム/日時
疑問なのですが本当にそんなにタバコが悪いのですかね?
たとえば舘ひろし氏。40年ヘビースモーカーだった人が禁煙しましたと持ち上げられていますが、舘氏が60歳の現在まで大病したと聞いたことはないしルックスも年齢より若く見える。
これだと、じゃあ俺も60歳で禁煙するわ、と逆説的になるのでは?とも思いますけれど。
また下世話になりますが舘氏がこのキャンペーン?でいくら貰ったのか?たぶん億だろうな、なんてことも考えます。
車内に排気ガスを送り込み自殺する方法はありますが、タバコの煙では死にません。
つまり、この50年間で肺がん含むがんが増えている原因は単純に車の増加だと思いますが・・・
喫煙男
2011/01/24 20:24

コメントする help

ニックネーム
本 文
出荷停止の禁煙補助薬チャンピックスが供給再開へ 医師の一分/BIGLOBEウェブリブログ
文字サイズ:       閉じる